Oligonucleotides for modulating the effects of cytomegalovirus infections
CA 2089666 C · Owner: Isis Pharmaceuticals Inc. · Inventors: Draper, Kenneth G.; Anderson, Kevin P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments oligonucleotides or , oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment meth-, ods of treatment of human cytomegalovirus are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 14, 1991 and granted January 7, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 14, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 14, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.